Literature DB >> 30057345

JAK Inhibitors for Treatment of Alopecia Areata.

Eddy H C Wang1, Brigitte N Sallee1, Christina I Tejeda2, Angela M Christiano3.   

Abstract

The advancement of genetic and preclinical studies has uncovered the mechanisms involved in the pathogenesis of alopecia areata (AA). The development of targeted therapies using small molecules blocking specific pathways for the treatment of AA is underway. By repurposing Food and Drug Administration-approved small molecule JAK inhibitors as treatments for AA, it has been demonstrated that JAK inhibitors can effectively reverse hair loss in patients with moderate to severe AA. In this review, we summarize and discuss the current preclinical and clinical studies on JAK inhibitors, as well as the prospects of using JAK inhibitors for the treatment of AA.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30057345      PMCID: PMC6475885          DOI: 10.1016/j.jid.2018.05.027

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  41 in total

1.  Treatment of Alopecia Areata With Tofacitinib.

Authors:  Omer Ibrahim; Cheryl B Bayart; Sara Hogan; Melissa Piliang; Wilma F Bergfeld
Journal:  JAMA Dermatol       Date:  2017-06-01       Impact factor: 10.282

2.  Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.

Authors:  Cheryl B Bayart; Katherine L DeNiro; Lars Brichta; Brittany G Craiglow; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2017-07       Impact factor: 11.527

Review 3.  JAK inhibitors in dermatology: The promise of a new drug class.

Authors:  William Damsky; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-01-28       Impact factor: 11.527

4.  Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).

Authors:  John E Harris; Mehdi Rashighi; Nhan Nguyen; Ali Jabbari; Grace Ulerio; Raphael Clynes; Angela M Christiano; Julian Mackay-Wiggan
Journal:  J Am Acad Dermatol       Date:  2015-12-11       Impact factor: 11.527

Review 5.  Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.

Authors:  Daniella M Schwartz; Michael Bonelli; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Rheumatol       Date:  2015-12-03       Impact factor: 20.543

6.  An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.

Authors:  A Jabbari; F Sansaricq; J Cerise; J C Chen; A Bitterman; G Ulerio; J Borbon; R Clynes; A M Christiano; J Mackay-Wiggan
Journal:  J Invest Dermatol       Date:  2018-02-13       Impact factor: 8.551

Review 7.  Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis.

Authors:  Lauren C Strazzulla; Eddy Hsi Chun Wang; Lorena Avila; Kristen Lo Sicco; Nooshin Brinster; Angela M Christiano; Jerry Shapiro
Journal:  J Am Acad Dermatol       Date:  2018-01       Impact factor: 11.527

8.  Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.

Authors:  Ali Jabbari; Zhenpeng Dai; Luzhou Xing; Jane E Cerise; Yuval Ramot; Yackov Berkun; Gina A Montealegre Sanchez; Raphaela Goldbach-Mansky; Angela M Christiano; Raphael Clynes; Abraham Zlotogorski
Journal:  EBioMedicine       Date:  2015-02-26       Impact factor: 8.143

9.  Differences in Comorbidity Profiles between Early-Onset and Late-Onset Alopecia Areata Patients: A Retrospective Study of 871 Korean Patients.

Authors:  Noo Ri Lee; Bo-Kyung Kim; Na Young Yoon; Sung-Yul Lee; Seok-Yong Ahn; Won-Soo Lee
Journal:  Ann Dermatol       Date:  2014-11-26       Impact factor: 1.444

10.  Transient Efficacy of Tofacitinib in Alopecia Areata Universalis.

Authors:  Florian Anzengruber; Julia-Tatjana Maul; Jivko Kamarachev; Ralph M Trüeb; Lars E French; Alexander A Navarini
Journal:  Case Rep Dermatol       Date:  2016-04-22
View more
  9 in total

1.  Comparison of hair manifestations in cardio-facio-cutaneous and Costello syndromes highlights the influence of the RAS pathway on hair growth.

Authors:  J Urban; L Qi; H Zhao; I Rybak; K A Rauen; M Kiuru
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-01-02       Impact factor: 6.166

2.  Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice.

Authors:  Eunjin Lee; Mingyu Kim; You Jeong Lee
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

Review 3.  Mouse Models of Alopecia Areata: C3H/HeJ Mice Versus the Humanized AA Mouse Model.

Authors:  Amos Gilhar; Rimma Laufer Britva; Aviad Keren; Ralf Paus
Journal:  J Investig Dermatol Symp Proc       Date:  2020-11

4.  Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02.

Authors:  Christos Tziotzios; Christos Petridis; Nick Dand; Chrysanthi Ainali; Jake R Saklatvala; Venu Pullabhatla; Alexandros Onoufriadis; Rashida Pramanik; David Baudry; Sang Hyuck Lee; Kristie Wood; Lu Liu; Seth Seegobin; Gregory A Michelotti; Su M Lwin; Evangelos A A Christou; Charles J Curtis; Emanuele de Rinaldis; Alka Saxena; Susan Holmes; Matthew Harries; Ioulios Palamaras; Fiona Cunningham; Gregory Parkins; Manjit Kaur; Paul Farrant; Andrew McDonagh; Andrew Messenger; Jennifer Jones; Victoria Jolliffe; Iaisha Ali; Michael Ardern-Jones; Charles Mitchell; Nigel Burrows; Ravinder Atkar; Cedric Banfield; Anton Alexandroff; Caroline Champagne; Hywel L Cooper; Sergio Vañó-Galván; Ana Maria Molina-Ruiz; Nerea Ormaechea Perez; Girish K Patel; Abby Macbeth; Melanie Page; Alyson Bryden; Megan Mowbray; Shyamal Wahie; Keith Armstrong; Nicola Cooke; Mark Goodfield; Irene Man; David de Berker; Giles Dunnill; Anita Takwale; Archana Rao; Tee-Wei Siah; Rodney Sinclair; Martin S Wade; Ncoza C Dlova; Jane Setterfield; Fiona Lewis; Kapil Bhargava; Niall Kirkpatrick; Xavier Estivill; Catherine M Stefanato; Carsten Flohr; Timothy Spector; Fiona M Watt; Catherine H Smith; Jonathan N Barker; David A Fenton; Michael A Simpson; John A McGrath
Journal:  Nat Commun       Date:  2019-03-08       Impact factor: 14.919

Review 5.  Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.

Authors:  Ana M Montilla; Francisco Gómez-García; Pedro J Gómez-Arias; Jesús Gay-Mimbrera; Jorge Hernández-Parada; Beatriz Isla-Tejera; Juan Ruano
Journal:  Dermatol Ther (Heidelb)       Date:  2019-10-13

6.  A photo-distributed papulopustular eruption and multiple squamous cell carcinomas in a patient on ruxolitinib.

Authors:  Urmi Khanna; Veronica Richardson; Elizabeth Hexner; Cuong V Nguyen; Rosalie Elenitsas; Misha Rosenbach
Journal:  JAAD Case Rep       Date:  2019-10-22

Review 7.  Immunopathology and Immunotherapy of Inflammatory Skin Diseases.

Authors:  Ahreum Song; Sang Eun Lee; Jong Hoon Kim
Journal:  Immune Netw       Date:  2022-02-14       Impact factor: 5.851

Review 8.  Pathomechanisms of immune-mediated alopecia.

Authors:  Alessandra Anzai; Eddy Hsi Chun Wang; Eunice Y Lee; Valeria Aoki; Angela M Christiano
Journal:  Int Immunol       Date:  2019-07-13       Impact factor: 5.071

Review 9.  Getting Under the Skin: Targeting Cutaneous Autoimmune Disease.

Authors:  Matthew D Vesely
Journal:  Yale J Biol Med       Date:  2020-03-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.